{"version":"1.0","type":"link","title":"Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study.","author_name":"Wang H 외","author_url":"https://prs-insight.online/author/Wang%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/98108","thumbnail_width":1200,"thumbnail_height":630}